Modality
mRNA
MOA
IL-17i
Target
FGFR
Pathway
Apoptosis
AMLBreast CaNMOSD
Development Pipeline
Preclinical
~Sep 2010
→ ~Dec 2011
Phase 1
~Mar 2012
→ ~Jun 2013
Phase 2
~Sep 2013
→ ~Dec 2014
Phase 3
~Mar 2015
→ ~Jun 2016
NDA/BLA
~Sep 2016
→ ~Dec 2017
Approved
Mar 2018
→ Jul 2028
ApprovedCurrent
NCT06143667
2,242 pts·NMOSD
2018-03→2028-07·Recruiting
2,242 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2028-07-052.3y awayPh3 Readout· NMOSD
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
Approved
Recruit…
Catalysts
Ph3 Readout
2028-07-05 · 2.3y away
NMOSD
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06143667 | Approved | NMOSD | Recruiting | 2242 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-3458 | Argenx | Preclinical | RET | |
| Nidaratamab | Krystal Biotech | Preclinical | RET |